March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Shushan Hovsepyan: My top 7 sessions to attend at the ESMO Sarcoma and Rare Tumor Annual Congress
Mar 18, 2025, 12:07

Shushan Hovsepyan: My top 7 sessions to attend at the ESMO Sarcoma and Rare Tumor Annual Congress

Shushan Hovsepyan, Editor-in-Chief of OncoDaily Medical Journal, shared a post on LinkedIn:

“The ESMO Sarcoma and Rare Tumor Annual Congress is approaching!

Some of the biggest discussions in sarcoma and rare tumors are about to happen.

Here are my top 7 sessions to attend:

  • Combination systemic treatments with immunotherapy.

Javier Martin-Broto (Madrid, Spain) – Are new combinations the game-changer we need?

  • T Cell Therapy: Next Questions.

Sandra D’Angelo (New York, US) – What’s next in making cell therapy effective for sarcomas?

  • Agnostic drug development: The new frontier in oncology?

Sandra Strauss (London, UK) – Could tumor-agnostic therapies reshape treatment strategies?

  • Global trends in sarcoma clinical trials: Disparities & efficiencies

Amalya Sargsyan (Yerevan, Armenia) – Why do trial access gaps still exist, and what can we do?

  • New systemic treatments & trial challenges in angiosarcoma.

Bernd Kasper (Mannheim, Germany) – Why are clinical trials so difficult, and how do we fix this?

  • Biology of leiomyosarcoma (LMS): What we now know.

Maria Cleofé Romagosa (Barcelona, Spain) – Are we any closer to real progress?

  • Long-term nirogacestat in desmoid tumors: Updated Phase III DeFi trial data.

Bernd Kasper (Mannheim, Germany) – A new standard of care?

Did I miss any key topics? Let me know if you have additions!”

Shushan Hovsepyan: My top 7 sessions to attend at the ESMO Sarcoma and Rare Tumor Annual Congress